Gold tier: mechanically validated evidence, with its primary source.
298 evidence items · page 11 / 12
Among female undergraduates in a tertiary institution in south eastern Nigeria who had been screened for cervical cancer, all were screened at a cost of ₦1,001–₦2,000.
Nigeriacancer du col de l'utéruspublished 2021Journal of preventive medicine and hygienePubMeddocument of 11 observations
83,593 womenOver 83,593 women were screened for cervical cancer in Nigeria.
Nigeriacancer du col de l'utérusAfrica CDCdocument of 52 observations
71.4 %Using a cut-off value of 0.45, the positive predictive value of squamous cell carcinoma antigen was 71.4%.
Nigeriacancer du col de l'utéruspublished 2025European journal of medical researchPubMeddocument of 8 observations
67.5 %67.5% of the respondents had heard of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2024Reproductive healthPubMeddocument of 16 observations
Nigeria has low cervical cancer screening and vaccination rates.
Nigeriacancer du col de l'utéruspublished 2024BMC infectious diseasesPubMeddocument of 10 observations
3.3 score_on_5_point_Likert_scaleThe median attitude score toward cervical cancer among rural women in North Central Nigeria was 3.3 on a five-point Likert scale.
Nigeriacancer du col de l'utéruspublished 2026Rural and remote healthPubMeddocument of 21 observations
53.5 %Over half (53.5%) of the respondents had heard of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2020The Pan African medical journalPubMeddocument of 5 observations
57.7 %Out of 23,409 women living with HIV who visited the sites during March to August 2023, 13,518 (57.7%) were eligible for cervical cancer screening.
Nigeriacancer du col de l'utérusobserved March to August 2023published 2026BMC health services researchPubMeddocument of 5 observations
732 women732 (7.1%) of the screened women had a positive screening test suggestive of precancerous lesions or cervical cancer.
Nigeriacancer du col de l'utérusobserved October 2020 to July 2021published 2023Reproductive healthPubMeddocument of 9 observations
0.929 odds_ratioTreatment delay was an independent predictor of lower brachytherapy utilization (p = 0.037, OR = 0.929, 95% CI = 0.868–0.996).
Nigeriacancer du col de l'utérusobserved March 2021 to June 2024PubMeddocument of 6 observations
19 %19% of the 231 women had basic information on the cause of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2021Cancer treatment and research communicationsPubMeddocument of 11 observations
59.2 %59.2% of rural women in North Central Nigeria had fair/good general knowledge of cervical cancer.
Nigeriacancer du col de l'utéruspublished 2026Rural and remote healthPubMeddocument of 21 observations
4 rankCervical cancer is the fourth most diagnosed cancer among women globally.
Nigeriacancer du col de l'utéruspublished 2023BMC women's healthPubMeddocument of 5 observations
46.9 %246 (46.9%) of the 514 surveyed women had good knowledge of cervical cancer screening.
Nigeriacancer du col de l'utéruspublished 2023African journal of reproductive healthPubMeddocument of 4 observations
27.3 %Awareness of cervical cancer screening methods was reported by 27.3% of respondents in a community health outreach program in Ituku, Enugu State, Nigeria.
Nigeriacancer du col de l'utérusobserved 2024published 2026Rural and remote healthPubMeddocument of 8 observations
26.6 %26.6% of rural women in North Central Nigeria cited hospitals as a source of information on cervical cancer.
Nigeriacancer du col de l'utéruspublished 2026Rural and remote healthPubMeddocument of 21 observations
12.2 %Only 12.2% of rural women in North Central Nigeria reported ever undergoing cervical cancer screening.
Nigeriacancer du col de l'utéruspublished 2026Rural and remote healthPubMeddocument of 21 observations
97.2 %420 (97.2%) of the respondents said they had not been screened for cervical cancer.
Nigeriacancer du col de l'utéruspublished 2023Cancer treatment and research communicationsPubMeddocument of 5 observations
315 women315 (43.0%) of VIA-positive women received treatment using thermal ablation.
Nigeriacancer du col de l'utérusobserved October 2020 to July 2021published 2023Reproductive healthPubMeddocument of 9 observations
84.3 %Uptake of pap smear increased to 84.3% in the intervention group post-intervention.
Nigeriacancer du col de l'utéruspublished 2022BMC women's healthPubMeddocument of 5 observations
42.3 %42.3% of rural women in North Central Nigeria recognized HPV infection as a risk factor for cervical cancer.
Nigeriacancer du col de l'utérus · infection à HPVpublished 2026Rural and remote healthPubMeddocument of 21 observations
65.5 %The South West region had the highest cervical cancer screening rate at 65.5%, while the North West region had the lowest at 22.4%.
Nigeriacancer du col de l'utérusobserved March to August 2023published 2026BMC health services researchPubMeddocument of 5 observations
60.3 %The health education intervention yielded a 60.3% net gain in uptake of cervical cancer screening post intervention.
Nigeriacancer du col de l'utéruspublished 2023African journal of reproductive healthPubMeddocument of 4 observations
290 cases290 out of 507 mothers living with HIV had knowledge of cervical cancer screening.
Nigeriacancer du col de l'utéruspublished 2026BMC public healthPubMeddocument of 8 observations
67,371 womenAmong the 83,593 women screened, 67,371 (81%) received visual inspection with acetic acid (VIA) as their primary screening method.
Nigeriacancer du col de l'utérusobserved 2021published 2023BMC public healthPubMeddocument of 12 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.